Zimlovisertib (PF-06650833) is a potent, selective, and orally bioavailable IRAK4 inhibitor, demonstrating low nanomolar IC50 values in cellular assays. It is a valuable research tool for investigating IRAK4s role in oncology, autoimmune, and inflammatory diseases, with utility in both in vitro and in vivo experimental models.